Evidence map›Paper›PMID 35219341›Full record

ArticleBiotechnology for biofuels and bioproducts2022

Rational and evolutionary engineering of Saccharomyces cerevisiae for production of dicarboxylic acids from lignocellulosic biomass and exploring genetic mechanisms of the yeast tolerance to the biomass hydrolysate.

Vratislav Stovicek, Laura Dato, Henrik Almqvist, Marie Schöpping, Ksenia Chekina, Lasse Ebdrup Pedersen, Anna Koza, Diogo Figueira, Freddy Tjosås, Bruno Sommer Ferreira and 3 more

Open access · goldAbstract read
In one paragraph

Article in Biotechnology for biofuels and bioproducts, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 19 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 5 countries.

Vratislav StovicekThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Laura DatoThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Henrik AlmqvistDepartment of Chemical Engineering, Lund University, P.O. Box 124, 221 00, Lund, Sweden.
Marie SchöppingDepartment of Chemical Engineering, Lund University, P.O. Box 124, 221 00, Lund, Sweden.
Ksenia ChekinaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Lasse Ebdrup PedersenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Anna KozaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Diogo FigueiraBiotrend S.A., Biocant Park Núcleo 04, Lote 2, 3060-197, Cantanhede, Portugal.
Freddy TjosåsBorregaard ApS, Hjalmar Wessels vei 6, 1721, Sarpsborg, Norway.
Bruno Sommer FerreiraBiotrend S.A., Biocant Park Núcleo 04, Lote 2, 3060-197, Cantanhede, Portugal.
Jochen ForsterThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark.
Gunnar LidénDepartment of Chemical Engineering, Lund University, P.O. Box 124, 221 00, Lund, Sweden.
Irina BorodinaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800, Kgs. Lyngby, Denmark. irbo@biosustain.dtu.dk.ORCID http://orcid.org/0000-0002-8452-1393
Novo Nordisk Foundation · DKLund University · SEBiocant · PTBorregaard (Norway) · NOUniversity of Copenhagen · DK

Funding

H2020 European Research Council 757384Novo Nordisk Fonden NNF20CC0035580Novo Nordisk Fonden NNF20OC0060809Seventh Framework Programme FP7-613771
6 · The paper itself

Abstract

backgroundLignosulfonates are significant wood chemicals with a $700 million market, produced by sulfite pulping of wood. During the pulping process, spent sulfite liquor (SSL) is generated, which in addition to lignosulfonates contains hemicellulose-derived sugars-in case of hardwoods primarily the pentose sugar xylose. The pentoses are currently underutilized. If they could be converted into value-added chemicals, overall economic profitability of the process would increase. SSLs are typically very inhibitory to microorganisms, which presents a challenge for a biotechnological process. The aim of the present work was to develop a robust yeast strain able to convert xylose in SSL to carboxylic acids.

resultsThe industrial strain Ethanol Red of the yeast Saccharomyces cerevisiae was engineered for efficient utilization of xylose in a Eucalyptus globulus lignosulfonate stream at low pH using CRISPR/Cas genome editing and adaptive laboratory evolution. The engineered strain grew in synthetic medium with xylose as sole carbon source with maximum specific growth rate (µ

conclusionsThe combined metabolic engineering and adaptive evolution approach provided a robust SSL-tolerant industrial strain that converts fermentable carbon content of the SSL feedstock into malic and succinic acids at low pH.in production yields reaching 0.1 mol and 0.065 mol per mol of total consumed carbon sources.. Moreover, our work suggests potential genetic background of the tolerance to the SSL stream pointing out potential gene targets for improving the tolerance to inhibitory industrial feedstocks.

Indexed as

Adaptive evolutionBiorefineriesDicarboxylic acidsHardwood spent sulfite liquorIndustrial yeastNext generation sequencingXylose

Identifiers

PMID35219341
PMCPMC8882276
OpenAlexW4214750413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.